SHANMUGA HOSPITAL LIMITED
	(Erstwhile known as Shanmuga Hospital Private Limited)

Our company was originally incorporated as a Private Limited Company under the name "Shanmuga Hospital Private Limited' on June 26, 2020, in accordance with the Companies Act, 2013. We received a fresh certificate of incorporation, bearing the corporate identification number U85110TZ2020PTC033974, from the Registrar of Companies, Central Registration Centre. Subsequently, our company converted into a public limited company, resulting in a name change to "Shanmupa Hospital Limited". This alteration was formally recorded in a new Certificate of Incorporation dated June 06, 2024, with the Corporate Identification Number U85110TZ2020PLC033974, issued by the Registrar of Companies, Central Processing Centre. For further details of change in name and registered office of our company, please refer to section titled "Our History and Certain Corporate Matters" beginning on page no 159 of the Prospectus.

1. Our Company, Directors, Promoters and Group Companies are parties to certain legal proceedings. Any adverse decision in such proceedings may have a material adverse effect on our business, results of operations and financial condition.

2. Our Company has limited operating history, and therefore investors may not be able to assess our prospects on the basis of historical results.

3. We are highly dependent on our healthcare professionals, including doctors, nurses that we engage on a consultancy basis, and our business and financial results could be impacted if we are not able to attract and retain such healthcare professionals.

4. Our Company Is yet to place orders for medical equipment proposed to be installed at our hospital. Any delay in placing orders or procurement of such equipment may delay the schedule of implementation and possibly increase the cost of commencing operations.

5. We generate certain revenues from the arrangements with government sponsored health schemes, any adverse change in these regulations/government policies related to such schemes may adversely affect our business, results of operations, cash flows and prospects.

For further details please refer to the chapter "Risk Factors" on page no. 23 of the Prospectus

The Equity Shares offered through Prospectus are proposed to be listed on the SME Platform of BSE Limited ("BSE SME'). Our Company has received in-principal approval letter dated January 22,2025 from BSE for using its name in this offer document for listing of our shares on the BSE SME. For the purpose of this Issue, the Designated Stock Exchange is the BSE Limited ("BSE"). The trading is proposed to commence on February 21, 2025.

* Subject to receipt of listing and trading approvals from the BSE Limited.

The Issue was subscribed to an extent of4.88 times i.e., Gross Subscription of Rs. 1,00,65,60,000 /- for 1,86,40,000 equity shares were based on the bid file received from BSE on the day after closure of the Issue received as against Rs. 20,61,72,000/- for 38,18,000 equity shares equity shares, (including subscription by Market Makers to the Issue). The Issue was subscribed to an extent of 2.36 times (after technical rejection and bids not banked), i.e. Net Subscription of Rs. 48,77,28,000/- for 90,32,000 equity shares after eliminating technically rejected and bid not banked applications.

Allocation: The Basis of Allotment was finalized in consultation with the Designated Slock Exchange - BSE on February 18, 2025.

A. Allocation to Market Maker (After Technical & Multiple Rejections and Withdrawal): The Basis of Allotment to the Market Maker, at the issue price of Rs. 54/- per Equity Share, was finalised in consultation with BSE. The category' was subscribed by 1.00 time. Tire total number of shares allotted in this category' is 1,92,000 Equity shares.

B. Allocation to Retail Individual Investors (After Technical & Multiple Rejections and Withdrawal): The Basis of Allotment to the Retail Individual Investors, at the issue price of Rs. 54/- per Equity Share, was finalized in consultation with BSE. The category was subscribed by 2,427 times i.e. for 77,20,000 Equity Shares. Total number of shares allotted in this category' is 31,80,000 Equity Shares to 1,590 successful applicants.

C. Allocation to Non Retail Applicants (Non Institutional Applicants and QIBs) (After Technical Rejections & Withdrawal): The Basis of Allotment to Other than Retail Individual Investors, at the issue price of Rs. 54/-per Equity Share, was finalized in consultation with BSE. The category was subscribed by 2,434 times i.e. for 10,86,000 Equity Shares. Total number of shares allotted in this category is 4,46,000 Equity Shares to 172 successful applicants.

The Board of Directors of the company at its meeting held on February 18, 2025 has approved the Basis of Allotment of Equity shares as approved by the Designated stock Exchange viz. BSE and at a meeting held on February 18, 2025 has authorized the corporate action for the transfer and allotment of the Equity Shares to various successful applicants.

In terms of the Prospectus dated February 06, 2025 and as per the SEBI (ICDR) Regulations wherein a minimum of 50% of the net offer of shares to the Public shall initially be made available for allotment to retail individual investors as the case may be. The balance net offer of shares to the public shall be made available for allotment to a) individual applicants oilier than retail investors and b) oilier investors, including Corporate Bodies / Institutions irrespective of number of shares applied for. The unsubscribed portion of the net offer to any one of the categories specified in (a) or (b) shall be made available for allocation in the oilier category', if so required. "For the purpose of sub-regulation (2) of regulations 253, if the retail individual investor category' is entitled to more than fifty per cent on proportionate basis, the retail individual investors shall be allocated that higher percentage".

The instructions to Self Certified Syndicate Banks for unblocking the amount has been processed on February' 18, 2025. Further, the CAN-cum-Refund advices and allotment advice and/or notices has been forwarded to the address/email id of the Applicants as registered with the depositories as filled in the application form on February' 18, 2025. In case the same is not received within 10 days, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary' accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on the BSE within three working days from the date of the closure of the Issue.

*Status as on February 05, 2025

INVESTORS PLEASE NOTE The details of the allotment made would also be hosted on the website of the Registrar to the Issuer, www.integratedregistry.in All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First' Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

	INTEGRATED REGISTRY MANAGEMENT SERVICES PRIVATE LIMITED
	No 30, Ramana Residency, 4th Cross, Sampige Road, Malleswaram, Bengaluru - 560003, India
	Telephone: 080-23460815/816/817/818 Email: smeipo@integratedindia.in Contact Person: S Giridhar Website: www.integratedregistry.in
	Investor Grievance Email: giri@integratedindia.in SEBI Registration Number: INR000000544 CIN: U74900TN2015PTC101466

DISCLAIMER CLAUSE OF BSE: IT IS TO BE DISTINCTLY UNDERSTOOD THAT THE PERMISSION GIVEN BY BSE LIMITED ("BSE") SHOULD NOT IN ANY WAY BE DEEMED OR CONSTRUED THAT THE CONTENTS OF THE PROSPECTUS OR THE PRICE AT WHICH THE EQUITY SHARES ARE OFFERED HAS BEEN CLEARED, SOLICITED OR APPROVED BY BSE, NOR DOES IT CERTIFY THE CORRECTNESS, ACCURACY OR COMPLETENESS OF ANY OF THE CONTENTS OF THE PROSPECTUS. THE INVESTORS ARE ADVISED TO REFER TO THE PROSPECTUS FOR THE FULL TEXT OF THE DISCLAIMER CLAUSE PERTAINING TO BSE.